Idioma:

Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review

Li, Nannan ; Beaudart, Charlotte ; Cauley, Jane A. ; Ing, Steven W. ; Lane, Nancy E. ; Reginster, Jean-Yves ; Silverman, Stuart ; Singer, Andrea J. ; Hiligsmann, Mickaël

PharmacoEconomics, 2023-04, Vol.41 (4), p.363-391 [Periódico revisado por pares]

Cham: Springer International Publishing

Texto completo disponível

Citações Citado por

Enviar para

Título:
Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review
Autor: Li, Nannan ; Beaudart, Charlotte ; Cauley, Jane A. ; Ing, Steven W. ; Lane, Nancy E. ; Reginster, Jean-Yves ; Silverman, Stuart ; Singer, Andrea J. ; Hiligsmann, Mickaël
Assuntos: Aged ; Androgens ; Bisphosphonates ; Bone Density Conservation Agents ; Bone Density Conservation Agents - therapeutic use ; Care and treatment ; Cost analysis ; Cost benefit analysis ; Cost-Effectiveness Analysis ; Demographic aspects ; Dietary supplements ; Diphosphonates ; Diphosphonates - therapeutic use ; Drugs ; Economic aspects ; Female ; Fractures ; Health Administration ; Health aspects ; Health Economics ; Health Policy ; Health services ; Human health sciences ; Humans ; Intervention ; Literature reviews ; Male ; Medicine ; Medicine & Public Health ; Men ; Methods ; Middle Aged ; Mortality ; Nutrition ; Osteoporosis ; Osteoporosis - diagnosis ; Osteoporosis - drug therapy ; Osteoporosis, Postmenopausal - drug therapy ; Osteoporotic Fractures - prevention & control ; Pharmacoeconomics and Health Outcomes ; Pharmacology ; Public Health ; Public Health, Environmental and Occupational Health ; Public health, health care sciences & services ; Quality of Life Research ; Santé publique, services médicaux & soins de santé ; Sciences de la santé humaine ; Systematic Review ; Womens health
É parte de: PharmacoEconomics, 2023-04, Vol.41 (4), p.363-391
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Undefined-1
content type line 23
scopus-id:2-s2.0-85147350049
Descrição: Background Osteoporosis is often considered to be a disease of women. Over the last few years, owing to the increasing clinical and economic burden, the awareness and imperative for identifying and managing osteoporosis in men have increased substantially. With the approval of agents to treat men with osteoporosis, more economic evaluations have been conducted to assess the potential economic benefits of these interventions. Despite this concern, there is no specific overview of cost-effectiveness analyses for the treatment of osteoporosis in men. Objectives This study aims (1) to systematically review economic evaluations of interventions for osteoporosis in men; (2) to critically appraise the quality of included studies and the source of model input data; and (3) to investigate the comparability of results for studies including both men and women. Methods A literature search mainly using MEDLINE (via Ovid) and Embase databases was undertaken to identify original articles published between 1 January, 2000 and 30 June, 2022. Studies that assessed the cost effectiveness of interventions for osteoporosis in men were included. The Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases and the International Osteoporosis Foundation osteoporosis-specific guideline was used to assess the quality of design, conduct, and reporting of included studies. Results Of 2973 articles identified, 25 studies fulfilled the inclusion criteria, classified into economic evaluations of active drugs ( n = 8) or nutritional supplements ( n = 4), intervention thresholds ( n = 5), screening strategies ( n = 6), and post-fracture care programs ( n = 2). Most studies were conducted in European countries ( n = 15), followed by North America ( n = 9). Bisphosphonates (namely alendronate) and nutritional supplements were shown to be generally cost effective compared with no treatment in men over 60 years of age with osteoporosis or prior fractures. Two other studies suggested that denosumab was cost effective in men aged 75 years and older with osteoporosis compared with bisphosphates and teriparatide. Intervention thresholds at which bisphosphonates were found to be cost effective varied among studies with a 10-year probability of a major osteoporotic fracture that ranged from 8.9 to 34.2% for different age categories. A few studies suggested cost effectiveness of screening strategies and post-fracture care programs in men. Similar findings regarding the cost effectiveness of drugs and intervention thresholds in women and men were captured, with slightly greater incremental cost-effectiveness ratios in men. The quality of the studies included had an average score of 18.8 out of 25 (range 13–23.5). Hip fracture incidence and mortality risk were mainly derived from studies in men, while fracture cost, treatment efficacy, and disutility were commonly derived from studies in women or studies combining both sexes. Conclusions Anti-osteoporosis drugs and nutritional supplements are generally cost effective in men with osteoporosis. Screening strategies and post-fracture care programs also showed economic benefits for men. Cost-effectiveness and intervention thresholds were generally similar in studies conducted in both men and women, with slightly greater incremental cost-effectiveness ratios in men.
Editor: Cham: Springer International Publishing
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Cost Effectiveness Analyses of Interventions for Osteoporosis in Men: A Systematic Literature Review

Li, Nannan ; Beaudart, Charlotte ; Cauley, Jane A. ; Ing, Steven W. ; Lane, Nancy E. ; Reginster, Jean-Yves ; Silverman, Stuart ; Singer, Andrea J. ; Hiligsmann, Mickaël

Cham: Springer International Publishing

Buscando em bases de dados remotas. Favor aguardar.